Simon Wan Yau Ming
Overview
Explore the profile of Simon Wan Yau Ming including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bilitou A, Were J, Farrer A, Rabe A, Ming S, Haq I, et al.
Clinicoecon Outcomes Res
. 2022 Apr;
14:189-203.
PMID: 35411162
Background: Guidelines for the management of dyslipidemias recommend intensive low-density lipoprotein (LDL-C) control through lifestyle advice and lipid-lowering drugs to reduce the risk of cardiovascular disease (CVD). Objective: This retrospective...
2.
Ming S, Haughney J, Ryan D, Small I, Lavorini F, Papi A, et al.
Int J Chron Obstruct Pulmon Dis
. 2020 Dec;
15:3093-3103.
PMID: 33273812
Introduction: The Fostair® 100/6 (BDP/FF) pressurized metered-dose inhaler, delivering an extrafine formulation, is licensed for asthma and COPD in the UK. However, its real-life effectiveness for COPD has not been...
3.
Kostikas K, Rhee C, Hurst J, Agostoni P, Cao H, Fogel R, et al.
Pragmat Obs Res
. 2020 Jun;
11:55-66.
PMID: 32581622
Purpose: Chronic obstructive pulmonary disease (COPD) and heart failure (HF) often occur concomitantly, presenting diagnostic and therapeutic challenges for clinicians. We examined the characteristics of patients prescribed adequate versus inadequate...
4.
Price D, Bosnic-Anticevich S, Pavord I, Roche N, Halpin D, Bjermer L, et al.
Clin Transl Allergy
. 2019 Aug;
9:41.
PMID: 31452870
Background: Blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO) concentration are established biomarkers in asthma, associated particularly with the risk of exacerbations. We evaluated the relationship of BEC...
5.
Park H, Yoon D, Lee H, Ban G, Ming S, Jie J, et al.
Respirology
. 2019 May;
24(10):972-979.
PMID: 31038269
Background And Objective: Mixed inhaler device use for asthma is associated with worse inhaler technique and outcomes. Given that relievers are commonly prescribed as pressurized metred-dose inhalers (pMDI), changing preventers...
6.
Ming S, Haughney J, Ryan D, Patel S, Ochel M, dAlcontres M, et al.
NPJ Prim Care Respir Med
. 2019 Feb;
29(1):3.
PMID: 30737400
Co-prescription of Aerochamber spacer with non-extrafine beclometasone diproprionate (non-EF BDP) is common but unlicensed. We report a comparison of inhaled corticosteroid (ICS)-related adverse events between patients co-prescribed Aerochamber compared to...
7.
Price D, Yang S, Ming S, Hardjojo A, Cabrera C, Papaioannou A, et al.
Int J Chron Obstruct Pulmon Dis
. 2018 Dec;
13:3937-3946.
PMID: 30587952
Background: Peak inspiratory flow (PIF) as generated through the resistance of a dry powder inhaler (DPI) device is a critical patient-dependent maneuver impacting the success of DPI medication delivery. Despite...
8.
Rhee C, van Boven J, Ming S, Park H, Kim D, Park H, et al.
J Allergy Clin Immunol Pract
. 2018 Oct;
7(3):934-942.
PMID: 30292924
Background: Inhaler usability and deposition differ between devices. Change of device may therefore have an impact on clinical and economic outcomes. Objective: To characterize clinical and economic asthma outcomes surrounding...
9.
Price D, Gefen E, Gopalan G, McDonald R, Thomas V, Ming S, et al.
PLoS One
. 2018 Jan;
13(1):e0191404.
PMID: 29364929
Introduction: Ventolin Nebules® (reference product; GlaxoSmithKline) was the first licensed nebulizer solution containing the rapid-onset, short-acting β2-agonist salbutamol. Salbutamol Steri-Neb™ (comparator; Teva Pharmaceuticals, Inc.) has the same chemical composition as...
10.
Ming S, Haughney J, Small I, Wolfe S, Hamill J, Gruffydd-Jones K, et al.
Respir Med
. 2017 Jul;
129:199-206.
PMID: 28732831
Objective: Asthma has a substantial impact on quality of life and health care resources. The identification of a more cost-effective, yet equally efficacious, treatment could positively influence the economic burden...